Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of SPARC-08-038 vs Caelyx in Breast/Ovarian Cancer
NCT03055143Phase 1Completed
- Sponsor
- Sun Pharma
- Start
- Sep 2008
- Primary completion
- Nov 2009
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 1, randomised, open-label trial of pegylated liposomal doxorubicin in breast cancer and ovarian cancer (2 arms), sponsored by Sun Pharma. Primary endpoint: Maximum measured plasma concentration at 336 hours. Started Sep 2008; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on NCT03055143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055143.